Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes

Haematologica

Volumn 97, Issue 6, 2012, Pages 895-902

  Sandes, Alex F ^a   Yamamoto, Mihoko ^a   Matarraz, Sergio ^b   Chauffaille, Maria de Lourdes L F ^a   Quijano, Sandra ^b   López, Antonio ^b   Oguro, Tsutomu ^c   Kimura, Eliza Y S ^a   Orfao, Alberto ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Centro de Investigacion del Cancer   (Spain)

^c HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

Author keywords

Flow cytometry; Immunophenotyping; Megakaryocytic dysplasia; Myelodysplastic syndromes; Platelets

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; CD61 ANTIGEN; CD63 ANTIGEN; CELL SURFACE PROTEIN; DUAL SPECIFICITY PHOSPHATASE 2; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MALE; MYELODYSPLASTIC SYNDROME; PILOT STUDY; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD PLATELETS; DUAL SPECIFICITY PHOSPHATASE 2; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; MALE; MEGAKARYOCYTES; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; PLATELET ACTIVATION; PROGNOSIS; RISK; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84862122790     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.057158     Document Type: Article

References (53)

1. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002, p.136-61.
2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19): 1872-85.
3. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. Chapter 5, Myelodysplastic syndromes/ neoplasms overview. p. 88-93.
4. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007;31(6): 727-36.
5. Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res. 2008;32(1):5-17.
6. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood. 2002;100(12):3887-96.
7. Lopez-Holgado N, Arroyo JL, Pata C, Villaron E, Sanchez GF, Martin A, et al. Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities. Leuk Res. 2004;28(11):1181-87.
8. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008; 22(6):1175-83.
9. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood. 2006;108(3):1037-44.
10. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98(4):979-87.
11. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102(1):394-403.
12. del Canizo MC, Fernandez ME, Lopez A, Vidriales B, Villaron E, Arroyo JL, et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica. 2003; 88(4):402-7.
13. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20(4):549-55.
14. Stachurski D, Smith BR, Pozdnyakova O, Andersen M, Xiao Z, Raza A, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res. 2008;32 (2):215-24.
15. Lorand-Metze I, Ribeiro E, Lima CS, Batista LS, Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res. 2007;31(2):147-55.
16. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom. 2010;78(3):154-68.
17. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94(8): 1124-34.
18. Tomer A. Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood. 2004; 104(9):2722-7.
19. Levine RF, Hazzard KC, Lamberg JD. The significance of megakaryocyte size. Blood. 1982;60(5):1122-31.
20. Rabellino EM, Levene RB, Leung LL, Nachman RL. Human megakaryocytes. II. Expression of platelet proteins in early marrow megakaryocytes. J Exp Med. 1981; 154(1):88-100.
21. Tomer A, Harker LA, Burstein SA. Flow cytometric analysis of normal human megakaryocytes. Blood. 1988;71(5):1244-52.
22. Tomer A, Friese P, Conklin R, Bales W, Archer L, Harker LA, et al. Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. Blood. 1989; 74(2):594-601.
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
24. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10.
25. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
26. Arroyo JL, Fernandez ME, Hernandez JM, Orfao A, San Miguel JF, del Canizo MC. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities. Hematol J. 2004;5(3):227-33.
27. Cutler JA, van de Loosdrecht AA, de Baca ME, Kalnoski M, Zehentner BK, Eidenschink L, et al. Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. Cytometry B Clin Cytom. 2011;80(3):150-7.
28. Ogata K. Diagnostic flow cytometry for lowgrade myelodysplastic syndromes. Hematol Oncol. 2008;26(4):193-8.
29. Scott BL, Wells DA, Loken MR, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood. 2008;112(7):2681-86.
30. Verburgh E, Achten A, Louw VJ, Brusselmans C, Delforge M, Boogaerts M, et al. A new disease categorization of lowgrade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007;21(4):668-77.
31. Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A, et al. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia. 2007;21(4):678-86.
32. Lorand-Metze I, Califani SM, Ribeiro E, Lima CS, Metze K. The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leuk Res. 2008;32(2):211-3.
33. Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, et al. Platelet counts and haemorragic diathesis in patients with myelodysplastic syndromes. Eur J Haematol. 2009;83:477-82.
34. Al Ameri A, Jabbour E, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, et al. Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. Clin Lymphoma Myeloma Leuk. 2011;11(2):237-41.
35. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22(3):538-43.
36. Orfao A, Ruiz-Arguelles A, Lacombe F, Ault K, Basso G, Danova M. Flow cytometry: its applications in hematology. Haematologica. 1995;80(1):69-81.
37. Berndt MC, Kabral A, Grimsley P, Watson N, Robertson TI, Bradstock KF. An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol. 1988;68(1):97-101.
38. Giannini S, Mezzasoma AM, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom. 2008;74(3):194-9.
39. Malik U, Dutcher JP, Oleksowicz L. Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma: a case report and review of the literature. Cancer. 1998; 82(9):1764-8.
40. Aziz KA. An acquired form of Bernard Soulier syndrome associated with acute myeloid leukemia. Saudi Med J. 2005;26(7): 1095-8.
41. Seidl C, Siehl J, Ganser A, Hofmann WK, Fischer M, Kirchmaier CM, et al. Platelet glycoprotein expression in patients with myelodysplastic syndrome. Thromb Res. 2000;100(1):27-34.
42. Curtis BR, Ali S, Glazier AM, Ebert DD, Aitman TJ, Aster RH. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion. 2002;42(9):1173-9.
43. Ikeda H, Mitani T, Ohnuma M, Haga H, Ohtzuka S, Kato T, et al. A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang. 1989;57(3):213-7.
44. Yamamoto N, Ikeda H, Tandon NN, Herman J, Tomiyama Y, Mitani T, et al. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka-platelets lack detectable GPIV (CD36). Blood. 1990;76(9): 1698-703.
45. Bierling P, Godeau B, Fromont P, Bettaieb A, Debili N, el Kassar N, et al. Posttransfusion purpura-like syndrome associated with CD36 (Naka) isoimmunization. Transfusion. 1995;35(9):777-82.
46. Yamamoto N, Akamatsu N, Sakuraba H, Yamazaki H, Tanoue K. Platelet glycoprotein IV (CD36) deficiency is associated with the absence (type I) or the presence (type II) of glycoprotein IV on monocytes. Blood. 1994;83(2):392-7.
47. Aota Y, Sumi M, Iguchi T, Okabe S, Gotoh A, Ohyashiki K. Type I CD36 deficiency in hematologic disorder. Haematologica. 2004; 89(8):EIM17.
48. Lee K, Godeau B, Fromont P, Plonquet A, Debili N, Bachir D, et al. CD36 deficiency is frequent and can cause platelet immunization in Africans. Transfusion. 1999;3(8):873-9.
49. Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion. 1996;36(4):331-4.
50. van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low-and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111(3):1067-77.
51. Houwerzijl EJ, Blom NR, van der Want JJ, Louwes H, Esselink MT, Smit JW, et al. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone maroow megakaryocytes in myelodysplastic patients. Blood. 2005;105 (9):3472-79.
52. Braun T, Carvalho G, Grosjean J, Ades L, Fabre C, Boehrer S, et al. Differentiating megakaryocytes in myelodysplastic syndromes succumb to mitochondrial derangement without caspase activation. Apoptosis. 2007;12(6):1101-08.
53. Houwerzijl EJ, Blom NR, van der Want JJ, Vellenga E, de Wolf JT. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia. 2006;20(11):1937-42.